Related references
Note: Only part of the references are listed.6,5-Fused Ring, C2-Salvinorin Ester, Dual Kappa and Mu Opioid Receptor Agonists as Analgesics Devoid of Anxiogenic Effects**
Nicholas S. Akins et al.
CHEMMEDCHEM (2022)
Opioid Ligands Addressing Unconventional Binding Sites and More Than One Opioid Receptor Subtype
Antonios Drakopoulos et al.
CHEMMEDCHEM (2022)
The Kappa Opioid Receptor and the Sleep of Reason: Cortico-Subcortical Imbalance Following Salvinorin-A
Genis Ona et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2022)
Sex- and β-arrestin-dependent effects of kappa opioid receptor-mediated ethanol consumption
Alexander R. French et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2022)
The G-protein biased kappa opioid agonists, triazole 1.1 and nalfurafine, produce non-uniform behavioral effects in male rhesus monkeys
Sally L. Huskinson et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2022)
Treatment of opioid overdose: current approaches and recent advances
Stevie C. Britch et al.
PSYCHOPHARMACOLOGY (2022)
Asymmetric Syntheses of (+)- and (-)-Collybolide Enable Reevaluation of kappa-Opioid Receptor Agonism
Sophia L. Shevick et al.
ACS CENTRAL SCIENCE (2022)
The kappa-opioid receptor agonist, triazole 1.1, reduces oxycodone self-administration and enhances oxycodone-induced thermal antinociception in male rats
C. Austin Zamarripa et al.
PSYCHOPHARMACOLOGY (2021)
Comprehensive overview of biased pharmacology at the opioid receptors: biased ligands and bias factors
Jolien De Neve et al.
RSC MEDICINAL CHEMISTRY (2021)
A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus
Steven Fishbane et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Functional Selectivity and Antinociceptive Effects of a Novel KOPr Agonist
Andrea Bedini et al.
FRONTIERS IN PHARMACOLOGY (2020)
Quantification of observable behaviors induced by typical and atypical kappa-opioid receptor agonists in male rhesus monkeys
S. L. Huskinson et al.
PSYCHOPHARMACOLOGY (2020)
A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating κ-opioid antagonism as a treatment for anhedonia
Andrew D. Krystal et al.
NATURE MEDICINE (2020)
Evaluation of Biased and Balanced Salvinorin A Analogs in Preclinical Models of Pain
Kelly F. Paton et al.
FRONTIERS IN NEUROSCIENCE (2020)
Kappa opioid receptors internalization is protective against oxygen-glucose deprivation through β-arrestin activation and Akt-mediated signaling pathway
Jihong Xu et al.
NEUROCHEMISTRY INTERNATIONAL (2020)
Strategies for Developing κ Opioid Receptor Agonists for the Treatment of Pain with Fewer Side Effects
Kelly F. Paton et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2020)
Biased Opioid Ligands
Abdelfattah Faouzi et al.
MOLECULES (2020)
Discovery of SHR0687, a Highly Potent and Peripheral Nervous System-Restricted KOR Agonist
Xin Li et al.
ACS MEDICINAL CHEMISTRY LETTERS (2020)
Biased Opioid Receptor Ligands: Gain without Pain
Tyler C. Beck et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2020)
Pharmacological Characterization of Levorphanol, a G-Protein Biased Opioid Analgesic
Valerie Le Rouzic et al.
ANESTHESIA AND ANALGESIA (2019)
Phosphoproteomic approach for agonist-specific signaling in mouse brains: mTOR pathway is involved in κ opioid aversion
Jeffrey J. Liu et al.
NEUROPSYCHOPHARMACOLOGY (2019)
Design and Synthesis of a Novel and Selective Kappa Opioid Receptor (KOR) Antagonist (BTRX-335140)
Miguel Guerrero et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
MP1104, a mixed kappa-delta opioid receptor agonist has anti-cocaine properties with reduced side-effects in rats
Diana V. Atigari et al.
NEUROPHARMACOLOGY (2019)
Cebranopadol, a Novel First-in-Class Analgesic Drug Candidate: First Experience With Cancer-Related Pain for up to 26 Weeks
E. Dietlind Koch et al.
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2019)
A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists
Kendall L. Mores et al.
FRONTIERS IN PHARMACOLOGY (2019)
Signaling Properties of Structurally Diverse Kappa Opioid Receptor Ligands: Toward in Vitro Models of in Vivo Responses
Amelia D. Dunn et al.
ACS CHEMICAL NEUROSCIENCE (2019)
Salvindolin elicits opioid system-mediated antinociceptive and antidepressant-like activities
Adam W. Keasling et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2019)
A novel finding of nalbuphine-6-glucuronide, an active opiate metabolite, possessing potent antinociceptive effects: Synthesis and biological evaluation
Ren-Jong Liang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Preclinical Testing of Nalfurafine as an Opioid-sparing Adjuvant that Potentiates Analgesia by the Mu Opioid Receptor-targeting Agonist Morphine
Shane W. Kaski et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2019)
Safety and efficacy of a combination of pethidine and levallorphan for pain relief during labor: An observational study
Masato Kinugasa et al.
JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH (2019)
Repeated Administration of Opra Kappa (LY2456302), a Novel, Short-Acting, Selective KOP-r Antagonist, in Persons with and without Cocaine Dependence
Brian Reed et al.
NEUROPSYCHOPHARMACOLOGY (2018)
A review of salvinorin analogs and their kappa-opioid receptor activity
Jeremy J. Roach et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2018)
The novel mu-opioid receptor agonist PZM21 depresses respiration and induces tolerance to antinociception
Rob Hill et al.
BRITISH JOURNAL OF PHARMACOLOGY (2018)
Structure of the Nanobody-Stabilized Active State of the Kappa Opioid Receptor
Tao Che et al.
CELL (2018)
Structurally Related Kappa Opioid Receptor Agonists with Substantial Differential Signaling Bias: Neuroendocrine and Behavioral Effects in C57BL6 Mice
Amelia D. Dunn et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2018)
Preclinical evaluation of the kappa-opioid receptor antagonist CERC-501 as a candidate therapeutic for alcohol use disorders
E. Domi et al.
NEUROPSYCHOPHARMACOLOGY (2018)
Optimization of a Series of Mu Opioid Receptor (MOR) Agonists with High G Protein Signaling Bias
Nicole M. Kennedy et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Mechanisms of signalling and biased agonism in G protein-coupled receptors
Denise Wootten et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2018)
In vitro and in vivo Pharmacological Activities of 14-O-Phenylpropyloxymorphone, a Potent Mixed Mu/Delta/Kappa-Opioid Receptor Agonist With Reduced Constipation in Mice
Roberta Lattanzi et al.
FRONTIERS IN PHARMACOLOGY (2018)
Butorphanol in Labour Analgesia
Jyotsna Yadav et al.
JOURNAL OF NEPAL MEDICAL ASSOCIATION (2018)
Synergistic interaction between the agonism of cebranopadol at nociceptin/orphanin FQ and classical opioid receptors in the rat spinal nerve ligation model
Thomas Christoph et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2018)
The analgesic and anti-inflammatory effects of Salvinorin A analogue -tetrahydropyran Salvinorin B in mice
K. F. Paton et al.
EUROPEAN JOURNAL OF PAIN (2017)
Highly Potent and Selective New Diphenethylamines Interacting with the κ-Opioid Receptor: Synthesis, Pharmacology, and Structure-Activity Relationships
Filippo Erli et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Cebranopadol, a novel first-in-class analgesic drug candidate: first experience in patients with chronic low back pain in a randomized clinical trial
Annette Christoph et al.
PAIN (2017)
The C-2 derivatives of salvinorin A, ethoxymethyl ether Sal B and β-tetrahydropyran Sal B, have anti-cocaine properties with minimal side effects
Amy W. M. Ewald et al.
PSYCHOPHARMACOLOGY (2017)
An overview of pharmacodynamic modelling, ligand-binding approach and its application in clinical practice
Mohammed Saji Salahudeen et al.
SAUDI PHARMACEUTICAL JOURNAL (2017)
Selective κ receptor partial agonist HS666 produces potent antinociception without inducing aversion after i.c.v. administration in mice
Mariana Spetea et al.
BRITISH JOURNAL OF PHARMACOLOGY (2017)
Opioid-type Respiratory Depressant Side Effects of Cebranopadol in Rats Are Limited by Its Nociceptin/Orphanin FQ Peptide Receptor Agonist Activity
Klaus Linz et al.
ANESTHESIOLOGY (2017)
Cannabinoid CB1 and CB2 Receptor Signaling and Bias
Mikkel Soes Ibsen et al.
CANNABIS AND CANNABINOID RESEARCH (2017)
Levorphanol use: past, present and future
Jeffrey Gudin et al.
POSTGRADUATE MEDICINE (2016)
6β-N-Heterocyclic Substituted Naltrexamine Derivative BNAP: A Peripherally Selective Mixed MOR/KOR Ligand
Dwight A. Williams et al.
ACS CHEMICAL NEUROSCIENCE (2016)
Estrogen facilitates and the kappa and mu opioid receptors mediate antinociception produced by intrathecal (-)-pentazocine in female rats
Douglas L. Robinson et al.
BEHAVIOURAL BRAIN RESEARCH (2016)
Heterodimerization of the kappa opioid receptor and neurotensin receptor 1 contributes to a novel β-arrestin-2-biased pathway
Haiqing Liu et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2016)
Biased agonism: An emerging paradigm in GPCR drug discovery
Zoran Rankovic et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2016)
The G-protein biased partial K opioid receptor agonist 6′-GNTI blocks hippocampal paroxysmal discharges without inducing aversion
Luca Zangrandi et al.
BRITISH JOURNAL OF PHARMACOLOGY (2016)
KAPPA-OPIOID ANTAGONISTS FOR PSYCHIATRIC DISORDERS: FROM BENCH TO CLINICAL TRIALS
William A. Carlezon et al.
DEPRESSION AND ANXIETY (2016)
G Protein-coupled Receptor Biased Agonism
Sima Y. Hodavance et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2016)
Will peripherally restricted kappa-opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential?
A. Albert-Vartanian et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2016)
Versatile Picklocks To Access All Opioid Receptors: Tuning the Selectivity and Functional Profile of the Cyclotetrapeptide c[Phe-D-Pro-Phe-Trp] (CJ-15,208)
Rossella De Marco et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Collybolide is a novel biased agonist of κ-opioid receptors with potent antipruritic activity
Achla Gupta et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria
Tarsis F. Brust et al.
SCIENCE SIGNALING (2016)
Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria
Tarsis F. Brust et al.
SCIENCE SIGNALING (2016)
Engineering therapeutic antibodies targeting G-protein-coupled receptors
Migyeong Jo et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2016)
Synthesis and Characterization of a Dual Kappa-Delta Opioid Receptor Agonist Analgesic Blocking Cocaine Reward Behavior
Andras Varadi et al.
ACS CHEMICAL NEUROSCIENCE (2015)
Structure-Activity Relationship Studies of Functionally Selective Kappa Opioid Receptor Agonists that Modulate ERK 1/2 Phosphorylation While Preserving G Protein Over βArrestin2 Signaling Bias
Kimberly M. Lovell et al.
ACS CHEMICAL NEUROSCIENCE (2015)
The kappa-opioid receptor antagonist, nor-binaltorphimine (nor-BNI), decreases morphine withdrawal and the consequent conditioned place aversion in rats
John E. Kelsey et al.
BEHAVIOURAL BRAIN RESEARCH (2015)
Salvinorin A analogues PR-37 and PR-38 attenuate compound 48/80-induced itch responses in mice
M. Salaga et al.
BRITISH JOURNAL OF PHARMACOLOGY (2015)
Intrinsic relative activities of κ opioid agonists in activating Gα proteins and internalizing receptor: Differences between human and mouse receptors
Kelly M. DiMattio et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2015)
Salvinorin A content in legal high products of Salvia divinorum sold in Mexico
Rafael Hernandez-Bello et al.
FORENSIC SCIENCE INTERNATIONAL (2015)
A Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of JDTic
Jeffrey J. Buda et al.
NEUROPSYCHOPHARMACOLOGY (2015)
Nociceptin and the nociceptin receptor in learning and memory
Rauel Andero
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2015)
The G Protein-Biased kappa-Opioid Receptor Agonist RB-64 Is Analgesic with a Unique Spectrum of Activities In Vivo
Kate L. White et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2015)
A Novel Method for Analyzing Extremely Biased Agonism at G Protein-Coupled Receptors
Edward L. Stahl et al.
MOLECULAR PHARMACOLOGY (2015)
A Study of Promethazine Hydrochloride and Pentazocine Intramuscular Sedation Along with 2 % Lidocaine Hydrochloride and Adrenaline and Comparison to Placebo Along with 2 % Lidocaine Hydrochloride and Adrenaline for Surgical Extraction of Mandibular Third Molar
F. Lalfamkima et al.
JOURNAL OF MAXILLOFACIAL & ORAL SURGERY (2015)
Antagonists of the kappa opioid receptor
Mariangela Urbano et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2014)
Safety, tolerability, and pharmacokinetic evaluation of single- and multiple-ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects
Stephen L. Lowe et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Synthesis and κ-Opioid Receptor Activity of Furan-Substituted Salvinorin A Analogues
Andrew P. Riley et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Synthesis and Pharmacological Evaluation of 5-Pyrrolidinylquinoxalines as a Novel Class of Peripherally Restricted κ-Opioid Receptor Agonists
Christian Bourgeois et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders
Linda M. Rorick-Kehn et al.
NEUROPHARMACOLOGY (2014)
Discovery of Spiro[cyclohexane-dihydropyrano[3,4-b]indole]-amines as Potent NOP and Opioid Receptor Agonists
Stefan Schunk et al.
ACS MEDICINAL CHEMISTRY LETTERS (2014)
Discovery of a Potent Analgesic NOP and Opioid Receptor Agonist: Cebranopadol
Stefan Schunk et al.
ACS MEDICINAL CHEMISTRY LETTERS (2014)
The kappa opioid receptor: from addiction to depression, and back
Laurence Lalanne et al.
FRONTIERS IN PSYCHIATRY (2014)
Novel Orally Available Salvinorin A Analog PR-38 Inhibits Gastrointestinal Motility and Reduces Abdominal Pain in Mouse Models Mimicking Irritable Bowel Syndrome
M. Salaga et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
Cebranopadol: A Novel Potent Analgesic Nociceptin/Orphanin FQ Peptide and Opioid Receptor Agonists
Klaus Linz et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
Identification of Novel Functionally Selective κ-Opioid Receptor Scaffolds
Kate L. White et al.
MOLECULAR PHARMACOLOGY (2014)
The macrocyclic tetrapeptide [D-Trp]CJ-15,208 produces short-acting κ opioid receptor antagonism in the CNS after oral administration
Shainnel O. Eans et al.
BRITISH JOURNAL OF PHARMACOLOGY (2013)
Functional Selectivity of 6′-Guanidinonaltrindole (6′-GNTI) at κ-Opioid Receptors in Striatal Neurons
Cullen L. Schmid et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Development of Functionally Selective, Small Molecule Agonists at Kappa Opioid Receptors
Lei Zhou et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Synthesis and Pharmacological Evaluation of Aminothiazolomorphinans at the Mu and Kappa Opioid Receptors
Brian A. Provencher et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Orvinols with Mixed Kappa/Mu Opioid Receptor Agonist Activity
Benjamin M. Greedy et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Development of κ Opioid Receptor Antagonists
F. Ivy Carroll et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Novel fentanyl-based dual μ/δ-opioid agonists for the treatment of acute and chronic pain
Alexander T. Podolsky et al.
LIFE SCIENCES (2013)
Selective κ Opioid Antagonists nor-BNI, GNTI and JDTic Have Low Affinities for Non-Opioid Receptors and Transporters
Thomas A. Munro et al.
PLOS ONE (2013)
Delta opioid receptors in brain function and diseases
Paul Chu Sin Chung et al.
PHARMACOLOGY & THERAPEUTICS (2013)
Physical Presence of Nor-Binaltorphimine in Mouse Brain over 21 Days after a Single Administration Corresponds to Its Long-Lasting Antagonistic Effect on κ-Opioid Receptors
Kshitij A. Patkar et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2013)
Discovery of Small Molecule Kappa Opioid Receptor Agonist and Antagonist Chemotypes through a HTS and Hit Refinement Strategy
Kevin J. Frankowski et al.
ACS CHEMICAL NEUROSCIENCE (2012)
Semisynthetic neoclerodanes as kappa opioid receptor probes
Kimberly M. Lovell et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2012)
Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 8. High affinity ligands for opioid receptors in the picomolar Ki range: Oxygenated N-(2-[1,1′-biphenyl]-4-ylethyl) analogues of 8-CAC
Mark P. Wentland et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2012)
Novel opioid cyclic tetrapeptides: Trp isomers of CJ-15,208 exhibit distinct opioid receptor agonism and short-acting κ opioid receptor antagonism
Nicolette C. Ross et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Antinociceptive effects of herkinorin, a MOP receptor agonist derived from salvinorin A in the formalin test in rats: New concepts in mu opioid receptor pharmacology: From a symposium on new concepts in mu-opioid pharmacology
Kenneth Lamb et al.
DRUG AND ALCOHOL DEPENDENCE (2012)
Contribution of mu and delta opioid receptors to the pharmacological profile of kappa opioid receptor subtypes
D. I. Brissett et al.
EUROPEAN JOURNAL OF PAIN (2012)
6′-Guanidinonaltrindole (6′-GNTI) Is a G Protein-biased κ-Opioid Receptor Agonist That Inhibits Arrestin Recruitment
Marie-Laure Rives et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Discovery and Pharmacological Evaluation of a Diphenethylamine Derivative (HS665), a Highly Potent and Selective κ Opioid Receptor Agonist
Mariana Spetea et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Blockade of kappa opioid receptors attenuates the development of depressive-like behaviors induced by cocaine withdrawal in rats
Elena Chartoff et al.
NEUROPHARMACOLOGY (2012)
Long-acting κ opioid antagonists nor-BNI, GNTI and JDTic: pharmacokinetics in mice and lipophilicity
Thomas A Munro et al.
BMC Pharmacology & Toxicology (2012)
Molecular Mechanisms of Opioid Receptor-dependent Signaling and Behavior
Ream Al-Hasani et al.
ANESTHESIOLOGY (2011)
Identification of short-acting κ-opioid receptor antagonists with anxiolytic-like activity
Matthew F. Peters et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2011)
Design and Discovery of a Selective Small Molecule κ Opioid Antagonist (2-Methyl-N-((2′-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine, PF-4455242)
Patrick R. Verhoest et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Discovery of Aminobenzyloxyarylamides as κ Opioid Receptor Selective Antagonists: Application to Preclinical Development of a κ Opioid Receptor Antagonist Receptor Occupancy Tracer
Charles H. Mitch et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Pentazocine-Induced Antinociception Is Mediated Mainly by μ-Opioid Receptors and Compromised by κ-Opioid Receptors in Mice
Haihua Shu et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
(-)-Pentazocine induces visceral chemical antinociception, but not thermal, mechanical, or somatic chemical antinociception, in μ-opioid receptor knockout mice
Soichiro Ide et al.
MOLECULAR PAIN (2011)
Pharmacological activity of Salvinorin A, the major component of Salvia divinorum
Joanna Listos et al.
PHARMACOLOGICAL REPORTS (2011)
N-naphthoyl-β-naltrexamine (NNTA), a highly selective and potent activator of μ/κ-opioid heteromers
Ajay S. Yekkirala et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Potential drug abuse therapeutics derived from the hallucinogenic natural product salvinorin A
Katherine M. Prevatt-Smith et al.
MEDCHEMCOMM (2011)
Pharmacological Characterization of 2-Methyl-N-((2′-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine (PF-04455242), a High-Affinity Antagonist Selective for κ-Opioid Receptors
S. Grimwood et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
Discovery of 8-azabicyclo[3.2.1]octan-3-yloxy-benzamides as selective antagonists of the kappa opioid receptor. Part 1
Todd A. Brugel et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2010)
Dynorphin, stress, and depression
Allison T. Knoll et al.
BRAIN RESEARCH (2010)
Asimadoline in the treatment of irritable bowel syndrome
Allen W. Mangel et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study
Hiroo Kumagai et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2010)
Kappa opioids and the modulation of pain
Bronwyn Kivell et al.
PSYCHOPHARMACOLOGY (2010)
Synthesis of CJ-15,208, a novel κ-opioid receptor antagonist
Nicolette C. Ross et al.
TETRAHEDRON LETTERS (2010)
Peptide Kappa Opioid Receptor Ligands: Potential for Drug Development
Jane V. Aldrich et al.
AAPS JOURNAL (2009)
Analgesic Efficacy of Peripheral κ-Opioid Receptor Agonist CR665 Compared to Oxycodone in a Multi-modal, Multi-tissue Experimental Human Pain Model Selective Effect on Visceral Pain
Lars Arendt-Nielsen et al.
ANESTHESIOLOGY (2009)
Structure-Based Design, Synthesis, and Biochemical and Pharmacological Characterization of Novel Salvinorin A Analogues as Active State Probes of the κ-Opioid Receptor
Feng Yan et al.
BIOCHEMISTRY (2009)
A bivalent ligand (KMN-21) antagonist for μ/κ heterodimeric opioid receptors
Shijun Zhang et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208
Roland E. Dolle et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
Syntheses and opioid receptor binding properties of carboxamido-substituted opioids
Mark P. Wentland et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
Mixed κ/μ Opioid Receptor Agonists: The 6β-Naltrexamines
Gerta Cami-Kobeci et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
The Effects of C-Terminal Modifications on the Opioid Activity of [N-BenzylTyr1]Dynorphin A-(1-11) Analogues
Kshitij A. Patkar et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Natural Products as Tools for Neuroscience: Discovery and Development of Novel Agents to Treat Drug Abuse
Thomas E. Prisinzano
JOURNAL OF NATURAL PRODUCTS (2009)
Nonprescription Use of Pain Relievers by Middle-Aged and Elderly Community-Living Adults: National Survey on Drug Use and Health
Dan G. Blazer et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2009)
NALFURAFINE PREVENTS 5′-GUANIDINONALTRINDOLE- AND COMPOUND 48/80-INDUCED SPINAL c-fos EXPRESSION AND ATTENUATES 5′-GUANIDINONALTRINDOLE-ELICITED SCRATCHING BEHAVIOR IN MICE
S. Inan et al.
NEUROSCIENCE (2009)
Zyklophin, a systemically active selective kappa opioid receptor peptide antagonist with short duration of action
Jane V. Aldrich et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Standard protecting groups create potent and selective κ opioids:: Salvinorin B alkoxymethyl ethers
Thomas A. Munro et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2008)
Synthesis and pharmacological evaluation of hydrophobic esters and ethers of butorphanol at opioid receptors
Brian S. Fulton et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
Novel D-amino acid tetrapeptides produce potent antinociception by selectively acting at peripheral κ-opioid receptors
Todd W. Vanderah et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2008)
Herkinorin analogues with differential β-arrestin-2 interactions
Kevin Tidgewell et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
A mechanistic model for the sex-specific response to nalbuphine and naloxone in postoperative pain
Smita Kshirsagar et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2008)
N-methylacetamide analog of salvinorin A: A highly potent and selective kappa-opioid receptor agonist with oral efficacy
Cecile Beguin et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Anxiolytic-Like effects of κ-opioid receptor antagonists in models of unlearned and learned fear in rats
Allison T. Knoll et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
Synthetic studies of neoclerodane diterpenes from Salvia divinorum:: Exploration of the 1-position
Kenneth G. Holden et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2007)
Subcutaneous, intrathecal and periaqueductal grey administration of asimadoline and ICI-204448 reduces tactile allodynia in the rat
Nadia L. Caram-Salas et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2007)
Long-acting κ opioid antagonists disrupt receptor signaling and produce noncompetitive effects by activating c-Jun N-terminal kinase
Michael R. Bruchas et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at μ, δ, and κ opioid receptors
Xuemei Peng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
The in vitro pharmacology of the peripherally restricted opioid receptor antagonists, alvimopan, ADL 08-0011 and methylnaltrexone
D. T. Beattie et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2007)
Oxycodone:: a pharmacological and clinical review
A. Ordonez Gallego et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2007)
Dynorphin A activates bradykinin receptors to maintain neuropathic pain
Josephine Lai et al.
NATURE NEUROSCIENCE (2006)
Dynorphin A, kappa opioid receptors and the antinociceptive efficacy of asimadoline in streptozotocin-induced diabetic rats
C. G. Jolivalt et al.
DIABETOLOGIA (2006)
Synthesis and in vitro evaluation of salvinorin A analogues:: Effect of configuration at C(2) and substitution at C(18)
Cecile Beguin et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2006)
Anti-inflammatory effects of contralateral administration of the κ-opioid agonist U-50,488H in rats with unilaterally induced adjuvant arthritis
I Bileviciute-Ljungar et al.
RHEUMATOLOGY (2006)
Psychopharmacology of the hallucinogenic sage Salvia divinorum
TE Prisinzano
LIFE SCIENCES (2005)
Effects of JDTic, a selective κ-opioid receptor antagonist, on the development and expression of physical dependence on morphine using a rat continuous-infusion model
FI Carroll et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2005)
Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats
PM Beardsley et al.
PSYCHOPHARMACOLOGY (2005)
Neoclerodane diterpenes as a novel scaffold for μ opioid receptor ligands
WW Harding et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
[Nα-BenzylTyr1,cyclo(D-Asp5,Dap8)]dynorphin A-(1-11)NH2 cyclized in the address domain is a novel K-opioid receptor antagonist
KA Patkar et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers
M Waldhoer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Synthesis and in vitro pharmacological evaluation of salvinorin A analogues modified at C(2)
C Béguin et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2005)
A bivalent ligand (KDAN-18) containing δ-antagonist and k-agonist pharmacophores bridges δ2 and k1 opioid receptor phenotypes
DJ Daniels et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Effects of the mixed mu/kappa opioid nalbuphine on cocaine-induced changes in subjective and cardiovascular responses in men
NK Mello et al.
NEUROPSYCHOPHARMACOLOGY (2005)
Kappa opioid antagonists: Past successes and future prospects
MD Metcalf et al.
AAPS JOURNAL (2005)
Peripheral kappa-opioid agonists for visceral pain
PJM Rivière
BRITISH JOURNAL OF PHARMACOLOGY (2004)
Effects of the mixed-action κ/μ opioid agonist 8-carboxamidocyclazocine on cocaine- and food-maintained responding in rhesus monkeys
GW Stevenson et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2004)
FE200041 (D-Phe-D-Phe-D-Nle-D-Arg-NH2):: A peripheral efficacious κ opioid agonist with unprecedented selectivity
TW Vanderah et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
Contralateral, ipsilateral and bilateral treatments with the K-opioid receptor agonist U-50,488H in mononeuropathic rats
I Bileviciute-Ljungar et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2004)
Synthesis and evaluation of the affinity toward μ-opioid receptors of atypical, lipophilic ligands based on the sequence c[-Tyr-Pro-Trp-Phe-Gly-]
G Cardillo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Pharmacological properties of JDTic:: a novel κ-opioid receptor antagonist
I Carroll et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2004)
Identification of (3R)-7-hydroxy-N-((1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide as a novel potent and selective opioid κ receptor antagonist
JB Thomas et al.
JOURNAL OF MEDICINAL CHEMISTRY (2003)
Effects of mixed-action κ/μ opioids on cocaine self-administration and cocaine discrimination by rhesus monkeys
CA Bowen et al.
NEUROPSYCHOPHARMACOLOGY (2003)
Analgesia from a peripherally active kappa-opioid receptor agonist in patients with chronic pancreatitis
JC Eisenach et al.
PAIN (2003)
CJ-15,208, a novel kappa opioid receptor antagonist from a fungus, Ctenomyces serratus ATCC15502
T Saito et al.
JOURNAL OF ANTIBIOTICS (2002)
Kappa opioid antagonist effects of the novel kappa antagonist 5′-guanidinonaltrindole (GNTI) in an assay of schedule-controlled behavior in rhesus monkeys
SS Negus et al.
PSYCHOPHARMACOLOGY (2002)
Salvinorin A:: A potent naturally occurring nonnitrogenous κ opioid selective agonist
BL Roth et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
8-carboxamidocyclazocine: A long-acting, novel benzomorphan
JM Bidlack et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
Diazabicyclononanones, a potent class of kappa opioid analgesics
U Holzgrabe et al.
FARMACO (2002)
Effects of a newly synthesized κ-opioid receptor agonist, TRK-820, on the discriminative stimulus and rewarding effects of cocaine in rats
T Mori et al.
PSYCHOPHARMACOLOGY (2002)
Effect of kappa opioid agonists on visceral nociception induced by uterine cervical distension in rats
A Sandner-Kiesling et al.
PAIN (2002)
Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: A double-blind randomized placebo-controlled trial
CS Yuan et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
Identification of the first trans-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine derivative to possess highly potent and selective opioid κ receptor antagonist activity
JB Thomas et al.
JOURNAL OF MEDICINAL CHEMISTRY (2001)
Transformation of a κ-opioid receptor antagonist to a κ-agonist by transfer of a guanidinium group from the 5′- to 6′-position of naltrindole
SK Sharma et al.
JOURNAL OF MEDICINAL CHEMISTRY (2001)
Analgesic and antiinflammatory effects of two novel κ-opioid peptides
W Binder et al.
ANESTHESIOLOGY (2001)
8-carboxamidocyclazocine analogues: Redefining the structure-activity relationships of 2,6-methano-3-benzazocines
MP Wentland et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2001)
5′-guanidinonaltrindole, a highly selective and potent κ-opioid receptor antagonist
RM Jones et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2000)
Synthesis and opioid receptor affinity of morphinan and benzomorphan derivatives:: Mixed κ agonists and μ agonists/antagonists as potential pharmacotherapeutics for cocaine dependence
JL Neumeyer et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)
Share Paper
